tiprankstipranks
Trending News
More News >
AbbVie (ABBV)
NYSE:ABBV
US Market

AbbVie (ABBV) Stock Forecast & Price Target

Compare
23,592 Followers
See the Price Targets and Ratings of:

ABBV Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
12 Buy
6 Hold
0 Sell
Based on 18 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$252.00
▲(8.86% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $252.00 with a high forecast of $289.00 and a low forecast of $223.00. The average price target represents a 8.86% change from the last price of $231.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"176":"$176","233":"$233","290":"$290","204.5":"$204.5","261.5":"$261.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$289.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":252,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$252.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$223.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[176,204.5,233,261.5,290],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.64,230.51384615384615,235.3876923076923,240.26153846153846,245.1353846153846,250.00923076923075,254.8830769230769,259.75692307692304,264.6307692307692,269.50461538461536,274.3784615384615,279.2523076923077,284.12615384615384,{"y":289,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.64,227.6676923076923,229.6953846153846,231.72307692307692,233.7507692307692,235.77846153846153,237.80615384615385,239.83384615384614,241.86153846153846,243.88923076923078,245.91692307692307,247.9446153846154,249.97230769230768,{"y":252,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.64,225.43692307692305,225.23384615384614,225.0307692307692,224.8276923076923,224.62461538461537,224.42153846153846,224.21846153846153,224.01538461538462,223.81230769230768,223.60923076923078,223.40615384615384,223.20307692307694,{"y":223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":177.931,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.245,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.575,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.793,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.592,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.522,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.275,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.226,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.694,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.299,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.313,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.666,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$289.00Average Price Target$252.00Lowest Price Target$223.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
$225
Hold
-2.81%
Downside
Reiterated
02/06/26
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
Bank of America Securities Analyst forecast on ABBV
Bank of America Securities
Bank of America Securities
$233$226
Hold
-2.38%
Downside
Reiterated
02/05/26
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Scotiabank Analyst forecast on ABBV
Scotiabank
Scotiabank
$280
Buy
20.95%
Upside
Reiterated
02/05/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
UBS
$240$230
Hold
-0.65%
Downside
Reiterated
02/05/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)
Guggenheim Analyst forecast on ABBV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
4.54%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Evercore ISI
$232$228
Buy
-1.51%
Downside
Reiterated
02/04/26
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
TD Cowen Analyst forecast on ABBV
TD Cowen
TD Cowen
$280
Buy
20.95%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Boston Scientific (NYSE: BSX)
William Blair Analyst forecast on ABBV
William Blair
William Blair
Buy
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), AbbVie (NYSE: ABBV) and Bio-Techne (NASDAQ: TECH)
Piper Sandler Analyst forecast on ABBV
Piper Sandler
Piper Sandler
$289
Buy
24.84%
Upside
Reiterated
02/02/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Intuitive Surgical (NASDAQ: ISRG) and Thermo Fisher (NYSE: TMO)
Morgan Stanley Analyst forecast on ABBV
Morgan Stanley
Morgan Stanley
$269
Buy
16.20%
Upside
Reiterated
01/28/26
Analysts Conflicted on These Healthcare Names: Korro Bio (NASDAQ: KRRO), Kazia Therapeutics (NASDAQ: KZIA) and AbbVie (NYSE: ABBV)
Citi
$235$230
Hold
-0.65%
Downside
Reiterated
01/28/26
AbbVie price target lowered to $230 from $235 at CitiAbbVie price target lowered to $230 from $235 at Citi
Goldman Sachs Analyst forecast on ABBV
Goldman Sachs
Goldman Sachs
$223
Hold
-3.67%
Downside
Reiterated
01/28/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and UnitedHealth (NYSE: UNH)
Wells Fargo Analyst forecast on ABBV
Wells Fargo
Wells Fargo
$260
Buy
12.31%
Upside
Reiterated
01/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AbbVie (NYSE: ABBV) and Acadia Healthcare (NASDAQ: ACHC)
Berenberg Bank Analyst forecast on ABBV
Berenberg Bank
Berenberg Bank
$270$275
Buy
18.79%
Upside
Reiterated
01/19/26
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV)
BMO Capital Analyst forecast on ABBV
BMO Capital
BMO Capital
$258
Buy
11.45%
Upside
Reiterated
01/15/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Glaukos (NYSE: GKOS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
$225
Hold
-2.81%
Downside
Reiterated
02/06/26
Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target
Bank of America Securities Analyst forecast on ABBV
Bank of America Securities
Bank of America Securities
$233$226
Hold
-2.38%
Downside
Reiterated
02/05/26
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV)
Scotiabank Analyst forecast on ABBV
Scotiabank
Scotiabank
$280
Buy
20.95%
Upside
Reiterated
02/05/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
UBS
$240$230
Hold
-0.65%
Downside
Reiterated
02/05/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), 10x Genomics (NASDAQ: TXG) and Oruka Therapeutics (NASDAQ: ORKA)
Guggenheim Analyst forecast on ABBV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
4.54%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Evercore ISI
$232$228
Buy
-1.51%
Downside
Reiterated
02/04/26
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
TD Cowen Analyst forecast on ABBV
TD Cowen
TD Cowen
$280
Buy
20.95%
Upside
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Boston Scientific (NYSE: BSX)
William Blair Analyst forecast on ABBV
William Blair
William Blair
Buy
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), AbbVie (NYSE: ABBV) and Bio-Techne (NASDAQ: TECH)
Piper Sandler Analyst forecast on ABBV
Piper Sandler
Piper Sandler
$289
Buy
24.84%
Upside
Reiterated
02/02/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Intuitive Surgical (NASDAQ: ISRG) and Thermo Fisher (NYSE: TMO)
Morgan Stanley Analyst forecast on ABBV
Morgan Stanley
Morgan Stanley
$269
Buy
16.20%
Upside
Reiterated
01/28/26
Analysts Conflicted on These Healthcare Names: Korro Bio (NASDAQ: KRRO), Kazia Therapeutics (NASDAQ: KZIA) and AbbVie (NYSE: ABBV)
Citi
$235$230
Hold
-0.65%
Downside
Reiterated
01/28/26
AbbVie price target lowered to $230 from $235 at CitiAbbVie price target lowered to $230 from $235 at Citi
Goldman Sachs Analyst forecast on ABBV
Goldman Sachs
Goldman Sachs
$223
Hold
-3.67%
Downside
Reiterated
01/28/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and UnitedHealth (NYSE: UNH)
Wells Fargo Analyst forecast on ABBV
Wells Fargo
Wells Fargo
$260
Buy
12.31%
Upside
Reiterated
01/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AbbVie (NYSE: ABBV) and Acadia Healthcare (NASDAQ: ACHC)
Berenberg Bank Analyst forecast on ABBV
Berenberg Bank
Berenberg Bank
$270$275
Buy
18.79%
Upside
Reiterated
01/19/26
Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV)
BMO Capital Analyst forecast on ABBV
BMO Capital
BMO Capital
$258
Buy
11.45%
Upside
Reiterated
01/15/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Glaukos (NYSE: GKOS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
xxx
Success Rate
21/28 ratings generated profit
75%
Average Return
+7.63%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.63% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
19/19 ratings generated profit
100%
Average Return
+18.63%
reiterated a buy rating last month
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.63% per trade.
2 Years
xxx
Success Rate
34/34 ratings generated profit
100%
Average Return
+28.56%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
0
0
0
0
0
Buy
40
37
32
28
26
Hold
26
39
38
32
23
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
66
76
70
60
49
In the current month, ABBV has received 26 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 252.00.
Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.01 with a range of $2.83 to $3.17. The previous quarter’s EPS was $2.71. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABBV is $3.01 with a range of $2.83 to $3.17. The previous quarter’s EPS was $2.71. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $14.63B with a range of $13.34B to $15.20B. The previous quarter’s sales results were $16.62B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s sales forecast for ABBV is $14.63B with a range of $13.34B to $15.20B. The previous quarter’s sales results were $16.62B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is 252.00.
    What is ABBV’s upside potential, based on the analysts’ average price target?
    AbbVie has 8.86% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABBV a Buy, Sell or Hold?
          AbbVie has a consensus rating of Moderate Buy which is based on 12 buy ratings, 6 hold ratings and 0 sell ratings.
            What is AbbVie’s price target?
            The average price target for AbbVie is 252.00. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $289.00 ,the lowest forecast is $223.00. The average price target represents 8.86% Increase from the current price of $231.5.
              What do analysts say about AbbVie?
              AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of ABBV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.